



ORIGINAL ARTICLE

Exercise capacity, lung and respiratory muscle function in substance use disorders



R. Mustafaoglu^{a,*}, A. Gorek Dilektaslı^b, R. Demir^c, E. Zirek^d, T. Birinci^e, E. Kaya Mutlu^f, C. Evren^g, A. Razak Ozdinciler^h

^a Division of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Istanbul University-Cerrahpasa, Istanbul, Turkey

^b Department of Pulmonary Medicine, Uludağ University School of Medicine, Bursa, Turkey

^c Department of Cardiology, Istanbul University-Cerrahpasa, Istanbul, Turkey

^d Division of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Bingöl University, Bingöl, Turkey

^e Division of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Istanbul Medeniyet University, Istanbul, Turkey

^f Division of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Bandirma Onyedi Eylül University, Balıkesir, Turkey

^g Research, Treatment, and Training Center for Alcohol and Substance Dependence, Bakırköy Training and Research Hospital for Psychiatry Neurology and Neurosurgery, Istanbul, Turkey

^h Division of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Biruni University, Istanbul, Turkey

Received 10 July 2021; accepted 20 December 2021

Available online 31 January 2022

KEYWORDS

Cough;
Dyspnoea;
Maximal respiratory pressure;
Pulmonary functions;
Substance use disorder

Abstract

Background: Substance use disorder (SUD) causes conditions such as cognitive and behavioral disorders, anxiety, depression, and social isolation it also causes acute airway inflammation by affecting airway bronchial dynamics. The current study aimed to investigate the lung function, respiratory muscle strength, and exercise capacity in patients with SUD.

Methods: One hundred-eighty three patients with SUD, a total of 119 healthy controls, 54 of whom were cigarette smokers and 65 of whom were non-smokers were included in the study. Spirometric tests, respiratory muscle strength (MIP and MEP), and the 6-Minute Walk Test (6-MWT) were assessed. The III National Health and Nutrition Examination Survey were used to evaluate respiratory symptoms in patients with SUD and cigarette smokers.

Results: 86.3% of the SUD patients included in the study were using heroin, 9.2% were cannabis, and 5.5% were spice. The most common symptom in both SUD patients and cigarette smokers was shortness of breath, wheezing, and sputum production. After post-hoc tests, the FVC ($p = 0.002$), FVC (%predicted) ($p < 0.0001$), FEV₁ ($p = 0.002$), FEV₁ (%predicted) ($p < 0.0001$), FEV₁/FVC (%) ($p < 0.0001$), PEF ($p < 0.0001$) and FEV₂₅₋₇₅ ($p < 0.0001$) lung function parameters were significantly lower in SUD patients than non-smokers. In addition, it was found that MIP

Abbreviations: SUD, Substance Use Disorder; 6-MWT, 6-Minute Walk Test; MIP, Maximum Inspiratory Pressure; MEP, Maximum Expiratory Pressure; DSM-V, Diagnostic and Statistical Manual of Mental Disorders, 5th edition; mMRC, Modified Medical Research Council Dyspnoea; FTND, Fagerström Test for Nicotine Dependence.

* Corresponding author at: İstanbul Üniversitesi-Cerrahpasa, Sağlık Bilimleri Fakültesi, Fizyoterapi ve Rehabilitasyon Bölümü, Alkent 2000 Mah. Yiğittürk Cad. No:5/9/1 Büyükçekmece, İstanbul, Türkiye.

E-mail address: rustem.mustafaoglu@iuc.edu.tr (R. Mustafaoglu).

<https://doi.org/10.1016/j.pulmoe.2021.12.009>

2531-0437/© 2022 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

($p < 0.0001$), MIP (%predicted) ($p < 0.0001$), MEP ($p < 0.0001$), and MEP (%predicted) ($p < 0.0001$) values of SUD patients were significantly lower than non-smokers.

Conclusion: The study findings indicate that substance use has an effect on lung functions and the most commonly reported symptoms are shortness of breath, wheezing, and sputum production. In addition, respiratory muscle strength and exercise capacity were decreased in SUD patients compared to non-smokers.

© 2022 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Introduction

In recent years, substance abuse has become a serious and growing problem worldwide and has threatened economic, social, legal, and health systems as an essential health problem and social problem in developed and developing countries.¹ It is estimated that one in four people in developed countries uses illicit drugs at some time in their life while one in six to seven people are at the risk of substance use disorder (SUD) in developing countries.^{2,3} The number of studies investigating the adverse effects of the substances in health is gradually increasing.^{4–6} Besides, SUD causes conditions such as cognitive and behavioral disorders, anxiety, depression, and social isolation it also causes acute airway inflammation by affecting airway bronchial dynamics and by preparing the ground for important histological changes in the airway mucosa.^{7–9}

The current studies, investigating the acute and chronic effects of SUD on the respiratory system, showed that the acute effect of substances on the respiratory system is mostly on bronchial dynamics.^{10,11} Moreover, it has been reported that short-term substance use causes decreased airway resistance due to bronchodilation.^{12,13} Long-term substance use might result in symptoms such as cough and abnormal sputum production, causing obstruction, hyperinflation, and changes in respiratory functions in the airways.^{9,11,14,15} Recent studies have suggested that substance use for a long time may lead to chronic bronchitis by causing airway inflammation and infection. Also, individuals who use cannabis and cocaine for a long time become susceptible to bacterial and viral infections since these substances cause tracheobronchial mucosal damage in the airway.¹⁵ Moreover, substance use has been reported to cause respiratory symptoms such as wheezing, cough, shortness of exercise, increased sputum production.^{14,16,17} Substance use also affects pulmonary functions and leads to obstruction in the airways during long-term use.^{18–22}

Many countries have national data showing the effect of substance use on respiratory functions.^{11,14, 19–23} In recent years, substance use has been increasing among young people in Turkey.^{24,25} To date, there are very limited studies on substance use in Turkey. Those studies reported data on substance use disorder prevalence, risk factors, sociodemographic determinants, and cognitive status.^{26–29} Studies on respiratory parameters in these individuals seem to be quite limited, and the need for such a study gains importance when the lack of research in this area is taken into account. However, accurate data to show the current situation in terms of the effects of substance use on the respiratory system is not available in Turkey. To the best of our knowledge, this is the first study to evaluate the respiratory muscle strength in patients with SUD. We

therefore aimed to conduct a field study to obtain accurate data regarding lung functions, respiratory muscle strength, and exercise capacity in patients with SUD. We hypothesized that lung functions, respiratory muscle strength, and exercise capacity will be more affected in patients with SUD than in cigarette smokers and non-smokers.

Methods

A prospective, cross-sectional observational study was conducted in Bakirkoy Prof. Dr. Mazhar Osman Research and Training Hospital for Psychiatry, Neurology, and Neurosurgery, Research, Treatment, and Training Center for Alcohol and Substance Dependence from June 2018 to June 2019. Ethical approval was obtained from the Human Research Ethics Committee of Bakirkoy Dr. Sadi Konuk Training and Research Hospital (Approval number: 2018/42) and conducted in conformity with the Declaration of Helsinki. Verbal and written explanations about the study were provided to all the participants and written informed consents were obtained.

Participants

The study sample consisted of 183 patients with SUD, a total of 119 healthy controls, 54 of whom were cigarette smokers and 65 of whom were non-smokers. Age-matched healthy controls consisted of hospital staff who met the eligibility criteria from the hospital staff list. Participants who were volunteers and met the inclusion criteria were enrolled in the study. The eligibility criteria for SUD participants were as follows; (1) age over 18 years old; (2) meeting current Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria for SUD³⁰; (3) using substances for over a year; (4) able to follow simple instructions; and (5) no pathology in visual ability and hearing. The eligibility criteria for cigarette smoker participants were as follows; (1) age over 18 years old; (2) smoking for over a year (active smokers); (3) able to follow simple instructions; and (4) no pathology in visual ability and hearing. The eligibility criteria for non-cigarette smoker participants were as follows; (1) age over 18 years old; (2) never smoked tobacco products (never smokers); (3) able to follow simple instructions; and (4) no pathology in visual ability and hearing. For all participants, the exclusion criteria were as follows: (1) current psychotic symptoms, (2) no physical disabilities (e.g., lower limb fractures, contractures) or medical problems (e.g., hypertension, heart attack, diabetes), or (3) respiratory system problems such as bronchiectasis, asthma, and tuberculosis, infectious health problem (e.g., HIV, hepatitis B).

Measurements

The socio-demographic information of the participants was recorded. In addition, pulmonary function tests, respiratory muscle strength, and 6-Minute Walk Test (6-MWT) were evaluated in the study. Furthermore, the dyspnea severity was assessed using the Modified Medical Research Council Dyspnoea (mMRC), and nicotine dependence was assessed using the Fagerström Test for Nicotine Dependence (FTND) among current cigarette smokers. The III National Health and Nutrition Examination Survey (NHANES III) was used to evaluate respiratory symptoms in patients with SUD and cigarette smokers.

Dyspnea

All participants' perceptions of dyspnea in daily living were evaluated using the modified Medical Research Council (mMRC) scale, which consists of five statements that describe almost the entire range of dyspnea from none (Grade 0) to almost complete incapacity (Grade 4).³¹

Nicotine dependence

The FTND, which is a standard instrument for assessing the intensity of physical addiction to nicotine, is used to measure the nicotine dependence related to cigarette smoking. It contains six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. The items are summed to yield a total score of 0-10 with a higher score indicating higher nicotine dependence.^{32,33}

Lung function tests

Lung function was measured using portable spirometry (Spirobank II; MIR, Rome, Italy). Measurements were performed according to the criteria of the American Thoracic Society (ATS) and the European Respiratory Society (ERS) guidelines.³⁴ Instructions and demonstrations were given to the participants before the spirometry measurements were taken. After three acceptable maneuvers, the highest values were selected for analysis.³⁵ Measurements were specified as percentages of the predicted values.

Respiratory muscle strength

The respiratory muscle strength was evaluated by the maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) according to ATS/ERS criteria using a portable MicroRPM device (Micro Medical, Basingstoke, UK). The highest value from five acceptable and reproducible attempts was recorded (i.e., a difference of $\leq 10\%$ among values) and is expressed as an absolute value (cmH₂O).³⁶ A percentage of the predicted values of MIP and MEP was specified as described by Black and Hyatt.³⁷

Exercise capacity

The 6-MWT, which is a reliable and valid test for evaluating exercise capacity, was performed according to the guideline of the ERS/ATS.³⁸ Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), perceived dyspnoea, and fatigue as measured using modified Borg scale (mBorg)

were assessed before and after the 6-MWTs. The distance in meters covered over the 6 minutes was recorded.³⁹ Also, the percentage of the predicted values was specified as described by Enright and Sherril.⁴⁰

Statistical analysis

Statistical Package for Social Science (SPSS) version 21.0 for Windows software (SPSS, Inc., Chicago, IL, USA) was used for all statistical analyses. Descriptive statistics, including frequency, the percentage for nominal variables, and mean and standard deviation for continuous variables were calculated. The Kolmogorov-Smirnov test was used to test the normality of data distribution. Demographic data were compared among the three groups by one-way analysis of variance (one-way ANOVA) for continuous variables and Chi-squared test for categorical variables. Dependent variables (lung function test, respiratory muscle strength, and the 6-MWT) were compared among the three groups by multivariate analysis of variance (MANOVA). In addition, covariance analysis (MANCOVA) was used in statistical analysis. The sex, age, weight, height, BMI, number of cigarettes smoked per day, duration of smoking, and score of the FTND were used as covariates, as they have an impact on the dependent variables. Once differences among the means were determined, the least significant difference (LSD) post hoc test was used. The significance level was set at $p < 0.05$.

The estimated sample size was derived from the online Raosoft sample size calculator (Raosoft, Inc., Seattle, WA; <http://www.raosoft.com/samplesize.html>). Raosoft online calculator is designed specifically for population surveys to calculate the sample size and determine how many responses are needed, to meet the desired confidence level with the margin of error (usually 5%). Therefore, it is highly recommended to be used for such a study with the consideration of the population size.⁴¹ The total population of heroin users in Istanbul is approximately 46,500.²⁸ Therefore, in order to achieve a confidence level of 90%, a response rate of 50%, and a 5% margin of error, a minimum sample size of 271 was required. However, from a total of only 217 patients with SUD screened for eligibility criteria, only 183 patients with SUD were enrolled in the study. A sample of 183 patients with SUD would provide a confidence level of 90% and a 6.08% margin of error which may affect the power of the study.

Results

A total of 217 patients with SUD who met the inclusion criteria were enrolled in the study. A total of 34 patients with SUD patients were excluded from the study because 26 of the participants could not comply with the spirometry test and 8 people refused to participate in the study voluntarily. As a result, a total of 302 volunteers, including 183 patients with SUD, a total of 119 healthy controls, 54 of whom were cigarette smokers and 65 of whom were non-smokers in the same age group were included in the study (Fig. 1).

Demographic and clinical characteristics

A comparison of the demographic and clinical characteristics of the participants is given in Table 1. The weight and BMI of




Fig. 1 Flow diagram.

SUD patients were significantly less than cigarette smokers and non-smokers ($p = 0.013$ and $p = 0.042$; $p = 0.018$ and $p = 0.048$, respectively). The mMRC score of SUD patients was significantly higher than cigarette smokers and non-smokers ($p < 0.0001$ and $p < 0.0001$, respectively). In addition to cigarette smoking, 86.3% of SUD patients were using heroin, 9.2% cannabis, and 5.5% spices. However, it is seen that some of the SUD patients in the study were polysubstance users, 37.1% of the patients used more than one type of substance, and 16.9% used at least 3 types of substances.

Respiratory related symptoms

Self-reported respiratory symptoms in SUD patients and cigarette smokers are presented in Table 2. It was observed that the most common symptoms in both SUD patients and cigarette smokers were shortness of breath when walking in a hurry or climbing slightly uphill, wheezing or whistling sound, and sputum. Except for chronic bronchitis and pneumonia, other respiratory-related symptoms in SUD patients were found to be statistically more common than cigarette smokers ($p < 0.05$).

Lung function and respiratory muscle strength parameters

There was a statistically significant difference between the mean scores of lung function test parameters between the groups [Wilks' Lambda (Λ)=0.80, $F=4.88$; $p < 0.0001$, $\eta^2=0.10$]. After post-hoc tests, the FVC ($p = 0.002$), FVC (%predicted) ($p < 0.0001$), FEV₁ ($p = 0.002$), FEV₁ (%predicted) ($p < 0.0001$), FEV₁/FVC (%) ($p < 0.0001$), PEF ($p < 0.0001$) and FEF₂₅₋₇₅ ($p < 0.0001$) parameters were statistically significantly lower in SUD patients than non-smokers. In addition, it was found that FVC (%predicted)

($p = 0.016$), FEV₁ (%predicted) ($p < 0.003$), FEV₁/FVC (%) ($p = 0.013$), PEF ($p < 0.001$), and FEF₂₅₋₇₅ ($p = 0.008$) values were significantly lower in cigarette smokers compared to non-smokers (Table 3). Gender [$F=5.66$, $p < 0.0001$, $\eta^2=0.12$] and duration of cigarette smoking [$F= 6.70$, $p < 0.0001$, $\eta^2=0.14$] were found as confounding factors for lung function test parameters. Similarly, there was a statistically significant difference between the groups in respiratory muscle strength values [Wilks' Lambda (Λ)=0.91, $F=5.75$; $p < 0.0001$, $\eta^2=0.04$]. After post-hoc tests, MIP ($p < 0.0001$), MIP (%predicted) ($p < 0.0001$), MEP ($p < 0.0001$), and MEP (%predicted) ($p < 0.0001$) values of SUD patients were significantly lower than non-smokers. In addition, it was found that MIP (%predicted) ($p < 0.024$) and MEP (%predicted) ($p < 0.027$) values were significantly lower in cigarette smokers compared to non-smokers (Table 3). Duration of cigarette smoking was found to be a confounding factor for respiratory muscle strength parameters [$F=6.82$, $p < 0.0001$, $\eta^2 = 0.04$]. However, other confounding factors had no effects on both lung functions and respiratory muscle strength.

Exercise capacity

A statistically significant difference was found between the groups in terms of 6-MWT [Wilks' Lambda (Λ)=0.54, $F=17.08$; $p < 0.0001$, $\eta^2=0.25$]. After post-hoc tests, a statistically significant difference was found between the SUD patients and non-smokers in terms of 6-MWD ($p < 0.0001$), 6-MWT (%predicted), ($p = 0.006$), Δ HR ($p < 0.0001$), Δ SBP ($p = 0.005$), Δ Dyspnea (Borg) ($p < 0.0001$) and Δ Perceived Exertion (Borg) ($p < 0.0001$). It was observed that Δ HR ($p < 0.0001$) and Δ SBP ($p = 0.005$) were significantly higher in SUD patients compared to cigarette smokers. In addition, it was found that Δ Dyspnea (Borg) ($p < 0.0001$) and

Table 1 Comparison of the clinical and socio-demographic characteristics of the participants.

	SUDs (n = 183)	Cigarette Smokers (n = 54)	Non-smokers (n = 65)	<i>p</i> ^{*,#}
Gender -Female/Male	15(8.2)/168(91.2)	5(9.3)/49(90.7)	6(9.2)/59(90.8)	0.951
Age (year)	29.77±8.1	29.61±9.99	28.71±9.49	0.692
Height (cm)	173.72±7.13	175.09±7.58	175.46±7.41	0.182
Weight (kg)	68.60±10.66	73.59±11.37	73.08±12.51	0.002^a
BMI (kg/cm ²)	22.71±3.14	23.94±2.94	23.78±4.39	0.011^b
Education period (year)	8.43±2.70	13.65±2.96	14.45±2.56	<0.0001^c
Age of starting substance use (year)	17.99±5.37	-	-	Na
Duration of substance use (year)	11.28±6.56	-	-	Na
Distribution of the substances used				
Heroin	158 (86.3)	-	-	Na
Cannabis	17 (9.3)	-	-	Na
Spice	8 (4.4)	-	-	Na
Age of starting smoking cigarette (year)	14.28±3.52	19.30±2.86	-	<0.001
Duration of cigarette smoking (year)	15.24±7.41	10.33±8.76	-	<0.001
Cigarette smoking (packs/year)	20.7±15.8	10.2±12.6	-	<0.001
FTND score	5.81±1.92	2.90±1.52	-	<0.001
mMRC	1.54±0.78	0.55±0.76	0.00±0.00	<0.0001^d

Data expressed as number (percentage) or mean ±SD for qualitative variables.

Abbreviations: FTND: Fagerström Test for Nicotine Dependence, mMRC: Modified Medical Research Council, na: not available

* Chi square test

One way ANOVA

^a The weight of SUD patients was statistically significantly lower than cigarette smokers and non-smokers ($p = 0.013$ and $p = 0.018$, respectively).

^b The SUD patients BMI was significantly lower than those cigarette smokers and no-smokers ($p = 0.042$ and $p = 0.048$, respectively).

^c Education period of the SUD patients was statistically significantly lower than cigarette smokers and non-smokers ($p < 0.0001$ and $p < 0.0001$, respectively).

^d The SUD patients mMRC score was significantly higher than those cigarette smokers and no-smokers ($p < 0.0001$ and $p < 0.0001$, respectively)

Table 2 The NHANES III respiratory symptoms in SUD patients, cigarette smokers, and non-smokers.

	SUDs (n = 183)	Cigarette Smokers (n = 54)	Non-Smokers (n = 65)	<i>p</i>
Has a doctor ever told you that you have chronic bronchitis?	19 (10.4%)	5 (9.3%)	-	0.081
Do you usually cough on most days for 3 consecutive months or more during the year?	72 (39.3%)	13 (24.1%)	-	<0.040
Do you bring up phlegm on most days for 3 consecutive months or more during the year?	117 (63.9%)	21 (38.9%)	-	<0.0001
Are you troubled by shortness of breath when hurrying on level ground or walking up a slight hill?	137 (74.9%)	25 (46.3%)	-	<0.0001
Have you had wheezing or whistling in your chest at any time during the past 12 months?	121 (66.1%)	26 (48.1%)	-	0.017
Apart from when you have a cold does your chest ever sound wheezy or whistling?	113 (61.7%)	18 (33.3%)	-	0.003
During the past 12 months have you had pneumonia?	7 (3.8%)	2 (3.7%)	-	0.956

Data expressed as number (percentage).

Abbreviations: NHANES: National Health Nutrition Examination Survey.

Table 3 Comparisons of the spirometry parameters and respiratory muscle strength values of the participants.

	SUDs (n = 183)	Cigarette Smokers (n = 54)	Non-smokers (n = 65)	F	p [#]	Post-hoc analysis p-values
FVC (L)	4.74±0.87	4.86±1.04	5.19±0.89	4.43	0.003	SUD-CS: 0.576 SUD-NS: 0.002 CS-NS: 0.059
FVC, % predicted	89.50±17.02	94.21±21.51	102.40±18.34	11.46	<0.0001	SUD-CS: 0.105 SUD-NS: <0.0001 CS-NS: 0.016
FEV ₁ (L)	3.93±0.78	4.01±0.91	4.32±0.67	5.28	0.003	SUD-CS: 0.520 SUD-NS: 0.002 CS-NS: 0.061
FEV ₁ , % predicted	89.50±17.02	89.50±17.02	89.50±17.02	9.27	<0.0001	SUD-CS: 0.598 SUD-NS: <0.0001 CS-NS: 0.003
FEV ₁ /FEVC (%)	81.22±8.46	83.58±7.85	87.91±7.50	21.25	<0.0001	SUD-CS: 0.127 SUD-NS: <0.0001 CS-NS: 0.013
PEF (L/s)	7.34±2.09	7.54±2.02	8.93±1.90	3.75	<0.0001	SUD-CS: 0.126 SUD-NS: <0.0001 CS-NS: <0.001
FEF ₂₅₋₇₅ (L/s)	4.17±1.32	4.33±1.23	5.06±1.31	11.10	<0.0001	SUD-CS: 0.373 SUD-NS: <0.0001 CS-NS: 0.008
FEV ₃ (L)	4.78±0.84	4.66±1.12	4.90±0.80	0.62	0.351	
FEV ₆ (L)	4.75±0.85	4.72±1.13	5.10±0.89	2.44	0.022	
MIP (cmH ₂ O)	89.51±26.09	94.88±24.87	105.61±30.10	4.20	<0.0001	SUD-CS: 0.072 SUD-NS: <0.0001 CS-NS: 0.672
MIP, %predicted	70.39±21.33	72.33±18.32	83.44±26.97	7.70	<0.0001	SUD-CS: 0.393 SUD-NS: <0.0001 CS-NS: 0.024
MEP (cmH ₂ O)	110.23±36.96	121.72±28.42	136.24±38.28	2.72	<0.0001	SUD-CS: 0.157 SUD-NS: <0.0001 CS-NS: 0.674
MEP, %predicted	47.08±15.60	50.82±12.96	57.26±11.56	10.68	<0.0001	SUD-CS: 0.132 SUD-NS: <0.0001 CS-NS: 0.027

Data expressed as mean ±SD for qualitative variables.

Abbreviations: FVC: Forced Vital Capacity; FEV₁: Forced Expiratory Volume in the First Second; PEF: Peak Expiratory Flow; FEF₂₅₋₇₅: Forced Mid-Expiratory Flow; FEV₃: Forced Expiratory Volume in 3 Seconds; FEV₆: Forced Expiratory Volume in 6 Seconds; MIP: Maximum Inspiratory Pressure; MEP: Maximum Expiratory Pressure; SUD: Substance Use Disorders; CS: Cigarette Smokers; NS: Non-Smokers.

[#] One way MANOVA; p < 0.05.

ΔPerceived Exertion (Borg) ($p < 0.0001$) were significantly higher in the cigarette smokers compared to the non-smokers (Table 4). Duration of cigarette smoking was found to be a confounding factor for exercise capacity parameters [$F=2.29$, $p = 0.035$, $\eta^2=0.04$]. However, other confounding factors had no effects on exercise capacity parameters.

Discussion

In this cross-sectional study, we observed that SUD patients started smoking earlier, smoked longer periods, consumed more cigarettes during the day, and had higher levels of nicotine addiction level than cigarette smokers. It was found that the most common symptoms in both SUD patients and cigarette smokers were shortness of breath, wheezing, and sputum production. In addition, SUD patients' lung function test parameters were significantly decreased compared to non-smokers, gender and smoking duration were confounding factors for lung function test parameters. Also, SUD patients had significantly lower respiratory muscle strength

and exercise capacity compared to non-smokers, and smoking duration was found to be a confounding factor.

In this study, 91.2% of SUD patients were male. Similarly, Demirci et al.²⁵ reported in their study that 82.4% of the participants were male. Charitonidi et al.⁴² also reported that 50.1% of SUD patients had primary and secondary education. Bükür et al.,⁴³ in their study on adolescent SUD patients, reported that 90.3% of the cases did not attend school and the average education period of the participants was 7.8 years. Similarly, in our study, we found that the education period of the SUD patients was 8.4 years. According to these findings, we can say that males constitute a significant portion of individuals using substances. The addiction to substance use may cause disruptions in education as well as negatively affect their health.

In the literature, the age of initiation of substance was reported as 14 years by Buchowski et al.⁴⁴ 16 years by Flemmen et al.,^{45,46} and 13.8 years in the study of Demirci et al.²⁵ In another study, Bükür et al.⁴³ reported the age of initiation substance use 14.6 years and the duration of substance use was 3.7 years. In our study, it was observed that the mean age of initiation of substance was 17.9 years, and

Table 4 Comparison of the functional exercise capacities of the participants.

	SUDs (n = 183)	Cigarette Smokers (n = 54)	Non-smokers (n = 65)	F	p [#]	Post-hoc analysis p- values
6-MWT (m)	512.17±80.60	535.46±76.88	577.45±93.33	14.77	<0.0001	SUD-CS: 0.091 SUD-NS: <0.0001 CS-NS: 0.059
6-MWT, %predicted	69.87±10.49	71.88±11.97	78.56±13.72	3.98	0.02	SUD-CS: 0.962 SUD-NS: 0.006 CS-NS: 0.051
ΔHR	+25.86±21.50	+11.85±7.80	+6.95±8.82	33.63	<0.0001	SUD-CS: <0.0001 SUD-NS: <0.0001 CS-NS: 0.063
ΔSBP	+13.12±13.79	+5.85±9.72	+7.55±8.49	10.23	<0.0001	SUD-CS: 0.005 SUD-NS: 0.005 CS-NS: 0.259
ΔDBP	+6.07±12.74	+4.40±8.09	+3.52±6.01	1.63	0.198	
ΔDyspnea (Borg)	+1.30±0.88	+1.18±0.95	+0.16±0.45	46.47	<0.0001	SUD-CS: 0.934 SUD-NS: <0.0001 CS-NS: <0.0001
Δ Perceived Exertion (Borg)	+1.44±0.75	+1.37±1.26	+0.33±0.71	40.94	<0.0001	SUD-CS: 0.896 SUD-NS: <0.0001 CS-NS: <0.0001

Data expressed as mean ±SD for qualitative variables.

Abbreviations: Δ: Change before and after 6-MWT; HR: Heart Rate; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; SUD: Substance Use Disorders;

CS: Cigarette Smokers; NS: Non-Smokers.

[#] One way MANOVA; p < 0.05.

the mean duration of use was 11.2 years. Flemmen et al.^{45,46} reported in their studies that the preferred substances for use by the SUD patients were heroin, cannabis, benzodiazepam, and ecstasy. Roessler⁴⁷ determined that the substances used by the SUD patients were heroin, ecstasy, cannabis, cocaine, benzodiazepam, while Demirci et al.²⁵ reported that cannabis, alcohol, spice, ecstasy, solvent/inhalants, benzodiazepam, and other substances. Burhan et al.⁴⁸ reported that 99% of individuals participating in their studies used cigarettes, 98% used heroin, 83% crack cocaine, and 83% cannabis. In our study, 86.3% of the participants were using heroin, 9.2% cannabis and 5.5% spice. In addition, 37.1% of the participants were found to use more than one type of substance (cocaine, ecstasy, etc.). As seen in the literature, SUD patients start using these substances from an early age and use more than one type of substance. In addition to the use of cigarettes, none of the participants in the study used a single type of substance, but users preferred one of them (heroin, cannabis and spices, etc.) more intensely than the others. In this case, it is seen that the SUD patients in the study were polysubstance users. Thus, it is impossible to determine from which substances the observed effects are caused. This condition seriously threatens both the respiratory and physical health of individuals.

Most, although not all, researchers have described increased reporting of respiratory symptoms among SUD patients similar to our findings.^{11,23,49} Macleod et al.²³ reported that in the cannabis users, the prevalence of chronic bronchitis is 14.7%, sputum production is 38.5%, shortness of breath is 47.5%, wheezing is 66.3%, and pneumonia is 3.6%. Also, Aldington et al.¹¹ reported that 28.6% of

cannabis users had a cough, 34.1% wheezing, and 30.8% chronic bronchitis. In the current study, 74.9% of the SUD patients had shortness of breath, 66.1% had wheezing, and 63.9% had sputum production. Similarly, 46.93% of cigarette smokers had shortness of breath, 48.1% had wheezing, and 38.9% had sputum production. Boto de los Bueis et al.⁵⁰ found a 41.9% prevalence of wheezing, a 44.4% prevalence of bronchial hyperreactivity, and a 22.03% prevalence of asthma among subjects who inhaled a mixture of heroin and cocaine vaporized on aluminum foil. Besides, Buster et al.⁴⁹ reported that 45% of individuals using heroin had mMRC dyspnea scale scores 0, 15% had 1, 18% had 2, and 22% had 3 and above. In our study, the distribution of mMRC dyspnea scale scores in SUD patients was 0 in 8.2%, 1 in 39.3%, 2 in 42.1%, and 3 and above in 10.4%. We think that the difference between the results of our study and the results of this study may be due to the presence of cannabis and spice users together with heroin in our study. Inhaling heroin and other substances involves repeated exposure to irritants rather than a single exposure to high concentrations of vapor. The physiopathogenic mechanism underlying the reactive airway is thought to cause an abnormal re-epithelialization and re-innervation of the bronchial mucosa after epithelial damage caused by initial exposure to the toxic substance. This can result in hypersensitivity of subepithelial receptors and, consequently, to maintained airway hyperresponsiveness.⁵⁰ Based on these possible mechanisms, evidence from this study suggests that SUD patients report more respiratory symptoms than smokers.

In recent years, substance use has been increasing in Turkey and in the rest of the world. Accordingly, the

number of studies investigating the harmful effects of substance use on health is increasing. Substance use has been reported to affect lung functions, decrease FVC and FEV₁, and predispose to airway obstruction in long-term use.^{18, 20–22,51,52} Macleod et al.²³ stated in their study that FVC was notably higher among cannabis users. In another study, Aldington et al.¹¹ found that both cannabis and tobacco use were associated with a decrease in the FEV₁/FVC, cannabis use did not affect FEV₁, and tobacco use caused a decrease in FEV₁. According to the authors, smoking cannabis was associated with a dose-related impairment of large airways function resulting in airflow obstruction and hyperinflation. Similarly, Taylor et al.,¹⁸ reported that there was a linear relationship between cannabis use and FEV₁/VC, and increased cannabis use over time was associated with a decrease in FEV₁/VC over time. It has been suggested that age, smoking, and weight are important determinants of FEV₁/VC, with marijuana use and daily smoking additionally affecting FEV₁/VC. Hancox et al.,²¹ suggested that cannabis was associated with evidence of hyperinflation and increased large airway resistance, with little evidence of airflow obstruction or impairment of gas transfer, whereas tobacco was associated with airflow obstruction, gas trapping, and lower transfer factors. According to the authors, smoking cannabis and tobacco have different physiological consequences for the lungs. Samoeiro et al.,²² reported that there was a weak correlation between declined FEV₁/FVC with length of time of smoking, the amount of cigarette consumption per day, time of cannabis inhalation, time of methamphetamine inhalation, and time of heroin injection. Buster et al.⁴⁹ reported a difference in FEV₁ from predicted values, finding that heroin smokers had an FEV₁ of 260 ml less than predicted FEV₁. Nightingale et al.,⁵³ found that lung function measured by FEV₁ declined by 90 ml annually, which was both statistically and clinically significant. Walker et al.⁵⁴ found heroin smokers developed early-onset emphysema, with a mean age of diagnosis being 41 years, suggesting likely early progression of disease compared with non heroin smokers. Burhan et al.⁴⁸ reported that just under one-half of 753 heroin smoker people had fixed airflow obstruction with an FEV₁/FVC <0.7. In our study, it was observed that the FVC, FVC (%predicted), FEV₁, FEV₁ (%predicted), FEV₁/FVC, PEF, and FEF_{25–75%} were decreased in SUD patients compared to non-smokers. In addition, cigarette smokers were found to be significantly lower in FVC (%predicted), FEV₁ (%predicted), FEV₁/FVC, PEF, and FEF_{25–75%} compared to non-smokers. Sex and duration of smoking were found to be confounding factors for lung function test parameters in SUD patients. In addition to cigarette smoking, the possible effect of heroin on the respiratory system is an increase in histamine release that causes pulmonary vein constriction, an increase in pulmonary capillary permeability, leading to pulmonary edema, bronchospasm, and hypersensitivity pneumonia.⁵⁵ Another possible mechanism is that it affects respiratory control centers, which can lead to fatal pulmonary depression.⁵⁶ The rapid decline in lung functions and the increase in respiratory symptoms in this population suggest heroin smoking is a driver of the decline in lung function. Some of the

discrepancies between the present findings and those of previous studies may be attributable to the relatively high levels of cumulative exposure seen in the present study population. In addition, in the current study, MIP, MIP (%predicted), MEP, and MEP (%predicted) values of the SUD patients significantly lower than the non-smokers. Although both MIP and MEP values were lower in SUD patients compared to cigarette smokers, this decrease was not significant. In addition, MIP (%predicted), and MEP (%predicted) were significantly lower in cigarette smokers compared to non-smokers. The smoking duration was found to be a confounding factor for respiratory muscle strength parameters. There is no study evaluating the respiratory muscle strength of SUD patients in the literature, and in this respect, our study is the first in this regard. The possible mechanism of decrease in respiratory muscle strength is the release of free radicals that occur in cigarette smoking and substance use into the vascular system, resulting in decreased blood flow and gas exchange to the respiratory muscle, which adversely affects respiratory muscle performance.

The number of studies investigating exercise capacity in SUD patients is limited in the literature. Patients with SUD are generally physically incompetent. This situation is associated with both unhealthy living habits and the effects of the substances used.^{57–59} Dolezal et al.⁵⁶ reported that VO₂max levels for men and women using methamphetamine were 30.6 and 23.2 mL/kg/min respectively. These values, based on the well-established reference values for age and sex, are classified as having poor cardiorespiratory fitness, with average rankings below 10% percentile for age and sex. Gimenez-Meseguer et al.,⁵⁹ similar to our study, evaluated the exercise capacities of the participants with the 6-MWT. It was reported that 6-MWT results before treatment in the experimental group were 618.8 meters and 623.2 meters in the control group. In our study, the 6-MWT results of SUD patients were found to be 512.17 meters, this value was 535.46 meters for cigarette smokers and 577.45 meters for non-smokers. In addition, there were significant differences in 6-MWT, mean heart rate, mean systolic blood pressure, shortness of breath, and fatigue scores of SUD patients compared to non-smokers. In this population, this may be due to decreased lung function and respiratory muscle strength, resulting in decreased exercise capacity. As a result, many SUD patients show physical impairment and a low level of fitness compared to the general population due to the nature of the substances they use. Improved exercise capacity may be important for SUD patients for the prevention or mitigation of a wide range of physical comorbidities.

Strengths and limitations

The main strengths of this study are that it is a general practice-based sample of non-smokers, cigarette smokers, and SUD patients. This study is also the first study in the literature to evaluate respiratory muscle strength in patients with SUD. The main limitations were that the study was cross-sectional and limited causality inference. Another limitation of the study is the inability to perform other laboratory and field measurements such as lower

limb muscle strength, physical activity, cardiopulmonary exercise test to better define the limitations of SUD patients. In addition, we lacked data on the possible effects of substance use over the lifetime of the participants, individual differences in inhalation methods used by cigarette smokers only, and both cigarette and substance smokers.

Clinical implications of the study and future research

This is the first study from Turkey providing data on the potential impact of SUD on lung functions, respiratory muscle strength, and exercise capacity. It is also the first study in the literature to provide results on respiratory muscle strength in SUD patients. The study findings indicate that there are some adverse respiratory effects from smoking substances and cigarettes. Limited data suggested that smoking both tobacco and substance may have additive adverse respiratory effects and long term substance use has been linked to an increase in respiratory symptoms.^{11,12,60} In the current study the most common respiratory symptoms in both SUD patients and cigarette smokers were shortness of breath, wheezing, and sputum production. The adverse effects of cigarette smoking on the lungs are well established. By contrast, the potential impact on lung health of substance use, with its wide range of toxins, is poorly understood. Smoking both cigarettes and substances may synergistically increase the risk of respiratory symptoms. Future studies with larger cohorts are needed, possibly in the context of a targeted public health intervention, to understand how best to avoid the personal and health costs associated with chronic respiratory disease. Moreover, studies should examine user characteristics associated with use trajectory groupings across primary drug types, and identifying factors associated with different lifetime drug use patterns will assist in the development of more targeted treatment services and policies. However, randomized controlled clinical trials will be needed to assess whether treatment services will be clinically and cost-effective in this population and how they will impact respiratory-related problems.

Conclusion

This study is the first study from Turkey providing data on the potential impact of SUD on the prevalence of respiratory symptoms, lung functions, and exercise capacity in a general practice population. The study findings indicate that substance use has an effect on lung functions and the most commonly reported symptoms are shortness of breath, wheezing, and sputum production. In addition, a decrease was observed in respiratory muscle strength and exercise capacity compared to non-smokers.

Ethical approval

All procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the Helsinki Declaration of Helsinki (1964) and its later amendments or comparable ethical standards.

Moreover, informed consent was obtained from all individuals included in the study (Approval number: 2018/42).

Funding

This study was supported by the Turkish Thoracic Society (Project No: Y-110/2018); however, it did not influence the interpretation of the results and conclusions obtained in the present study.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgments

The authors would like to thank Dr. Ishtiaq Ahmed PT for his editing support.

We are grateful to our patients who participated in the study.

References

1. Walker ER, Druss BG. Cumulative burden of comorbid mental disorders, substance use disorders, chronic medical conditions, and poverty on health among adults in the U.S.A. *Psychol Health Med.* 2017;22(6):727–35. <https://doi.org/10.1080/13548506.2016.1227855>.
2. Lai HM, Cleary M, Sitharthan T, Hunt GE. Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990-2014: A systematic review and meta-analysis. *Drug Alcohol Depend.* 2015;154:1–13. <https://doi.org/10.1016/j.drugalcdep.2015.05.031>.
3. Skidmore CR, Kaufman EA, Crowell SE. Substance use among college students. *Child Adolesc Psychiatr Clin N Am.* 2016;25(4):735–53. <https://doi.org/10.1016/j.chc.2016.06.004>.
4. Baggio S, Studer J, Mohler-Kuo M, Daeppen J-B, Gmel G. Concurrent and simultaneous polydrug use among young Swiss males: use patterns and associations of number of substances used with health issues. *Int J Adolesc Med Health.* 2014;26(2):217–24. <https://doi.org/10.1515/ijamh-2013-0305>.
5. Schulte MT, Hser Y-I. Substance use and associated health conditions throughout the lifespan. *Public Health Rev.* 2013;35(2):3. <https://doi.org/10.1007/BF03391702>.
6. Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. *Drug Test Anal.* 2014;6(1-2):39–45. <https://doi.org/10.1002/dta.1506>.
7. Daley DC. Family and social aspects of substance use disorders and treatment. *J Food Drug Anal.* 2013;21(4):S73–6. <https://doi.org/10.1016/j.jfda.2013.09.038>.
8. Conner KR, Pinquart M, Gamble SA. Meta-analysis of depression and substance use among individuals with alcohol use disorders. *J Subst Abuse Treat.* 2009;37(2):127–37. <https://doi.org/10.1016/j.jsat.2008.11.007>.
9. Gates P, Jaffe A, Copeland J. Cannabis smoking and respiratory health: consideration of the literature. *Respirology.* 2014;19(5):655–62. <https://doi.org/10.1111/resp.12298>.
10. Wilson KC, Saukkonen JJ. Acute respiratory failure from abused substances. *J Intensive Care Med.* 2004;19(4):183–93. <https://doi.org/10.1177/0885066604263918>.

11. Aldington S, Williams M, Nowitz M, et al. Effects of cannabis on pulmonary structure, function and symptoms. *Thorax*. 2007;62(12):1058–63. <https://doi.org/10.1136/thx.2006.077081>.
12. Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. *Arch Intern Med*. 2007;167(3):221–8. <https://doi.org/10.1001/archinte.167.3.221>.
13. Grassin-Delyle S, Naline E, Buenestado A, et al. Cannabinoids inhibit cholinergic contraction in human airways through pre-junctional CB1 receptors. *Br J Pharmacol*. 2014;171(11):2767–77. <https://doi.org/10.1111/bph.12597>.
14. Taylor DR, Poulton R, Moffitt TE, Ramankutty P, Sears MR. The respiratory effects of cannabis dependence in young adults. *Addiction*. 2000;95(11):1669–77. <https://doi.org/10.1046/j.1360-0443.2000.951116697.x>.
15. Ribeiro LI, Ind PW. Effect of cannabis smoking on lung function and respiratory symptoms: a structured literature review. *NPJ Prim Care Respir Med*. 2016;26:16071. <https://doi.org/10.1038/npjpcrm.2016.71>.
16. Reid P, McKenzie J, Copeland L, Elton R, Macleod J, Robertson J. Cannabis use, respiratory symptoms and lung function, in a North Edinburgh primary care population. *Thorax*. 2011;66(Suppl 4):A174–5. <https://doi.org/10.1136/thoraxjnl-2011-201054c.263>.
17. Martinasek MP, McGrogan JB, Maysonet A. A Systematic review of the respiratory effects of inhalational marijuana. *Respir Care*. 2016;61(11):1543–51. <https://doi.org/10.4187/respcare.04846>.
18. Taylor DR, Fergusson DM, Milne BJ, et al. A longitudinal study of the effects of tobacco and cannabis exposure on lung function in young adults. *Addiction*. 2002;97(8):1055–61. <https://doi.org/10.1046/j.1360-0443.2002.00169.x>.
19. Tan WC, Lo C, Jong A, et al. Marijuana and chronic obstructive lung disease: a population-based study. *CMAJ*. 2009;180(8):814–20. <https://doi.org/10.1503/cmaj.081040>.
20. Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years. *JAMA*. 2012;307(2):173–81. <https://doi.org/10.1001/jama.2011.1961>.
21. Hancox RJ, Poulton R, Ely M, et al. Effects of cannabis on lung function: a population-based cohort study. *Eur Respir J*. 2010;35(1):42–7. <https://doi.org/10.1183/09031936.00065009>.
22. Samoedro E, Yunus F, Antariksa B, Nurwidya F. Spirometry findings among drug users in the Indonesian National Narcotics and illicit drug Bureau Rehabilitation Center. *J Nat Sci Biol Med*. 2017;8(1):69–74. <https://doi.org/10.4103/0976-9668.198353>.
23. Macleod J, Robertson R, Copeland L, McKenzie J, Elton R, Reid P. Cannabis, tobacco smoking, and lung function: a cross-sectional observational study in a general practice population. *Br J Gen Pract*. 2015;65(631):e89–95. <https://doi.org/10.3399/bjgp15X683521>.
24. Evren C, Ogel K, Demirci AC, Evren B, Yavuz BG, Bozkurt M. Prevalence of lifetime tobacco, alcohol and drug use among 10th grade students in Istanbul. *Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology*. 2014;24(3):201–10. <https://doi.org/10.5455/bcp.20140131023259>.
25. Çiftçi Demirci A, Erdoğan A, Yalçın Ö, et al. Sociodemographic characteristics and drug abuse patterns of adolescents admitted for substance use disorder treatment in Istanbul. *Am J Drug Alcohol Abuse*. 2015;41(3):212–9. <https://doi.org/10.3109/00952990.2014.973961>.
26. İlhan MN, Arikan Z, Kotan Z, et al. Prevalence and socio-demographic determinants of tobacco, alcohol, substance use and drug misuse in general population in Turkey. *Noro Psikiyatr Ars*. 2016;53(3):205–12. <https://doi.org/10.5152/npa.2015.10050>.
27. Ünübol H, Sayar GH. Substance use and its risk factors in Turkey: a nationally representative sample study. *J Ethn Subst Abuse*. 2020;1–23. <https://doi.org/10.1080/15332640.2020.1781731>.
28. Ünübol H, Sayar GH. Prevalence and sociodemographic determinants of substance use in Turkey. *Eur Addict Res*. 2021;27(6):447–56. <https://doi.org/10.1159/000515399>.
29. Cengel HY, Bozkurt M, Evren C, Umut G, Keskinilic C, Agachanli R. Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder. *Psychiatry Res*. 2018;262:46–54. <https://doi.org/10.1016/j.psychres.2018.01.046>.
30. Association AP. *Diagnostic and statistical manual of mental disorders (DSM-5®)*. American Psychiatric Pub; 2013.
31. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. *Thorax*. 1999;54(7):581–6. <https://doi.org/10.1136/thx.54.7.581>.
32. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. *Br J Addict*. 1991;86(9):1119–27. <https://doi.org/10.1111/j.1360-0443.1991.tb01879.x>.
33. Uysal MA, Kadakal F, Karsidag C, Bayram NG, Uysal O, Yilmaz V. Fagerstrom test for nicotine dependence: reliability in a Turkish sample and factor analysis. *Tuberk Toraks*. 2004;52(2):115–21.
34. Brusasco V, Crapo R, Viegi G; American Thoracic Society; European Respiratory Society. Coming together: the ATS/ERS consensus on clinical pulmonary function testing. *Eur Respir J*. 2005 Jul;26(1):1–2. doi: 10.1183/09031936.05.00034205.
35. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. *Eur Respir J*. 2005;26(5):948–68. <https://doi.org/10.1183/09031936.05.00035205>.
36. ATS/ERS Statement on respiratory muscle testing. *Am J Respir Crit Care Med*. 2002;166(4):518–624. <https://doi.org/10.1164/rccm.166.4.518>.
37. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. *Am Rev Respir Dis*. 1969;99(5):696–702. <https://doi.org/10.1164/arrd.1969.99.5.696>.
38. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. *Eur Respir J*. 2014;44(6):1428–46. <https://doi.org/10.1183/09031936.00150314>.
39. Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF. Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. *Arch Phys Med Rehabil*. 2010;91(2):221–5. <https://doi.org/10.1016/j.apmr.2009.10.017>.
40. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. *Am J Respir Crit Care Med*. 1998;158:1384–7. <https://doi.org/10.1164/ajrccm.158.5.9710086>.
41. Meysamie A, Taei F, Mohammadi-Vajari M-A, Yoosefi-Khanghah S, Emamzadeh-Fard S, Abbassi M. Sample size calculation on web, can we rely on the results. *J Med Stat Informat*. 2014;2(1):3. <https://doi.org/10.7243/2053-7662-2-3>.
42. Charitonidi E, Studer J, Gaume J, Gmel G, Daepfen J-B, Bertholet N. Socioeconomic status and substance use among Swiss young men: a population-based cross-sectional study. *BMC Public Health*. 2016;16:333. <https://doi.org/10.1186/s12889-016-2949-5>.
43. Bükür HS, Demir E, Yüncü Z, Gülen F, Midyat L, Tanaç R. Effects of volatile substance abuse on the respiratory system in adolescents. *Multidiscip Respir Med*. 2011;6(3):161–8. <https://doi.org/10.1186/2049-6958-6-3-161>.
44. Buchowski MS, Meade NN, Charboneau E, et al. Aerobic exercise training reduces cannabis craving and use in non-treatment seeking cannabis-dependent adults. *PLoS One*. 2011;6(3):e17465. <https://doi.org/10.1371/journal.pone.0017465>.
45. Flemmen G, Unhjem R, Wang E. High-intensity interval training in patients with substance use disorder. *Biomed Res Int*. 2014;2014:616935. <https://doi.org/10.1155/2014/616935>.

46. Flemmen G, Wang E. Impaired aerobic endurance and muscular strength in substance use disorder patients: implications for health and premature death. *Med (Baltimore)*. 2015;94(44): e1914. <https://doi.org/10.1097/MD.0000000000001914>.
47. Roessler KK. Exercise treatment for drug abuse-A Danish pilot study. *Scand J Public Health*. 2010;38(6):664–9. <https://doi.org/10.1177/1403494810371249>.
48. Burhan H, Young R, Byrne T, et al. Screening heroin smokers attending community drug services for COPD. *Chest*. 2019;155(2):279–87. <https://doi.org/10.1016/j.chest.2018.08.1049>.
49. Buster MC, Rook L, van Brussel GH, van Ree J, van den Brink W. Chasing the dragon, related to the impaired lung function among heroin users. *Drug Alcohol Depend*. 2002;68(2):221–8. [https://doi.org/10.1016/s0376-8716\(02\)00193-x](https://doi.org/10.1016/s0376-8716(02)00193-x).
50. Boto de los Bueis A, Pereira Vega A, Sánchez Ramos JL, et al. Bronchial hyperreactivity in patients who inhale heroin mixed with cocaine vaporized on aluminum foil. *Chest*. 2002;121(4):1223–30. <https://doi.org/10.1378/chest.121.4.1223>.
51. Tan WC, Lo C, Jong A, et al. Marijuana and chronic obstructive lung disease: a population-based study. *CMAJ*. 2009;180(8):814–20. <https://doi.org/10.1503/cmaj.081040>.
52. Drummond MB, Merlo CA, Astemborski J, et al. The effect of HIV infection on longitudinal lung function decline among injection drug users: a prospective cohort. *AIDS*. 2013;15;27(8):1303–11. <https://doi.org/10.1097/QAD.0b013e32835e395d>.
53. Nightingale R, Mortimer K, Giorgi E, et al. Screening heroin smokers attending community drug clinics for change in lung function: a cohort study. *Chest*. 2020;157(3):558–65. <https://doi.org/10.1016/j.chest.2019.11.006>.
54. Walker PP, Thwaite E, Amin S, Curtis JM, Calverley PM. The association between heroin inhalation and early onset emphysema. *Chest*. 2015;148(5):1156–63. <https://doi.org/10.1378/chest.15-0236>.
55. Self TH, Shah SP, March KL, Sands CW. Asthma associated with the use of cocaine, heroin, and marijuana: a review of the evidence. *J Asthma*. 2017;54(7):714–22. <https://doi.org/10.1080/02770903.2016.1259420>.
56. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. *Addiction*. 1999;94(7):961–72. <https://doi.org/10.1046/j.1360-0443.1999.9479612.x>.
57. Dolezal BA, Chudzynski J, Storer TW, et al. Eight weeks of exercise training improves fitness measures in methamphetamine-dependent individuals in residential treatment. *J Addict Med*. 2013;7(2):122–8. <https://doi.org/10.1097/ADM.0b013e318282475e>.
58. Mamen A, Martinsen E. The aerobic fitness of substance abusers voluntarily participating in a rehabilitation project. *J Sports Med Phys Fitness*. 2009;49(2):187–93.
59. Giménez-Meseguer J, Tortosa-Martínez J, Remedios Fernández-Valenciano MdL. Benefits of exercise for the quality of life of drug-dependent patients. *J Psychoactive Drugs*. 2015;47(5):409–16. <https://doi.org/10.1080/02791072.2015.1102991>.
60. Tashkin DP, Simmons MS, Sherrill DL, Coulson AH. Heavy habitual marijuana smoking does not cause an accelerated decline in FEV1 with age. *Am J Respir Crit Care Med*. 1997;155(1):141–8. <https://doi.org/10.1164/ajrccm.155.1.9001303>.